Meeting
2016 ASCO Annual Meeting
Blood baseline neutrophil count to predict bevacizumab efficacy in glioblastoma.
Authors
Aurelie Bertaut
Georges-Francois Leclerc Cancer Center, Dijon, France
Aurelie Bertaut , Romain Boidot , Rachid Madkouri , Coureche guillaume Kaderbhai , Julie Vincent , Bruno Chauffert , Francois Ghiringhelli
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 34, 2016 (suppl; abstr 2024)
DOI
10.1200/JCO.2016.34.15_suppl.2024
Abstract #
2024
Poster Bd #
213
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolomide in newly diagnosed, MGMT-non-methylated glioblastoma patients.
First Author: Ulrich Herrlinger
Poster
2023 ASCO Annual Meeting
Depth of radiographic response (DpR) and time to tumor regrowth (TTG) to predict overall survival following anti-VEGF therapy in recurrent glioblastoma.
First Author: Benjamin M. Ellingson
Poster
2022 ASCO Annual Meeting
A phase II, multicenter, single-arm trial of eribulin in patients with bevacizumab-resistant recurrent glioblastoma.
First Author: Masamichi Takahashi
Poster
2021 ASCO Annual Meeting
Safety and efficacy study of retifanlimab and epacadostat in combination with radiation and bevacizumab in patients with recurrent glioblastoma.
First Author: Jian Li Campian